Obi Greenman
Vorstandsvorsitzender bei CERUS CORPORATION
Vermögen: 5 Mio $ am 31.05.2024
Profil
Mr. William M.
Greenman is a President, Chief Executive Officer & Director at Cerus Corp.
He is on the Board of Directors at Cerus Corp.
Mr. Greenman was previously employed as an Independent Director by Aduro BioTech, Inc., an Independent Director by Chinook Therapeutics, Inc., and a Senior Vice President-Biotech Division by Baxter International, Inc. He received his undergraduate degree from Stanford University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CERUS CORPORATION
1,62% | 01.04.2024 | 2 989 614 ( 1,62% ) | 5 Mio $ | 31.05.2024 |
Aktive Positionen von Obi Greenman
| Unternehmen | Position | Beginn |
|---|---|---|
| CERUS CORPORATION | Vorstandsvorsitzender | 21.04.2011 |
Ehemalige bekannte Positionen von Obi Greenman
| Unternehmen | Position | Ende |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 11.08.2023 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01.01.1995 |
| CHINOOK THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Obi Greenman
| Stanford University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CERUS CORPORATION | Health Technology |
| BAXTER INTERNATIONAL INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
